Asian Spectator

ACN Newswire Business

Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference

  • Written by ACN Newswire - Press Releases

Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 12th Clinical Trials on Alzheimer's Disease Conference

TOKYO, Dec 2, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that three oral presentations and eight poster presentations, highlighting the latest data on its Alzheimer's disease / dementia pipeline including anti-amyloid beta (Abeta) protofibril antibody BAN2401, orexin receptor antagonist lemborexant and a simple blood diagnostic for Alzheimer's disease (AD), will be given at the 12th Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in San Diego, California in the United States, from December 4 to 7, 2019. BAN2401 is being jointly developed by Eisai and Biogen Inc. In addition, the simple blood diagnostics for AD are being jointly developing by Eisai and Sysmex Corporation.

For BAN2401, the persistance of brain Abeta levels in patients with early AD at the beginning of the open label extension phase of the Phase II study (Study 201) will be presented in Late-Breaking Oral Communications Session. Study 201 is a first late-stage study which successfully demonstrated the potential disease-modifying effects on both clinical function and Abeta accumulation in the brain. In addition, the study design and current status of ongoing Clarity AD (Study 301) will be presented.

Meanwhile, for the investigational sleep-wake regulation agent lemborexant, the further data analysis results from Phase II clinical study (Study 202) for AD patients with irregular sleep-wake rhythm disorder (ISWRD) will be given.

In addition, regarding the creation of the simplified blood diagnostics for AD, jointly developed with Sysmex, the latest data of the fully automated protein assay system using the Sysmex's automated protein measurement immunoassay platform HISCLTM series will be presented.Eisai is aiming to realize prevention and cure of dementia through a holistic approach to dementia drug discovery research based on a foundation of over 35 years of experience of drug discovery activities in the area of Alzheimer's disease / dementia. Eisai is striving to create innovative medicines as soon as possible in order to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, patients and their families.

About BAN2401

BAN2401 is a humanized monoclonal antibody for Alzheimer's disease (AD) that is the result of a strategic research alliance between Eisai and BioArctic. BAN2401 selectively binds to neutralize and eliminate soluble, toxic Abeta aggregates (protofibril) that are thought to contribute to the neurodegenerative process in AD. As such, BAN2401 may have the potential to have an effect on disease pathology and to slow down the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of AD pursuant to an agreement concluded with BioArctic in December 2007. Currently, a global clinical phase III study (Clarity AD) of BAN2401 in early AD is underway.

About the Joint Development Agreement between Eisai and Biogen for AD

Eisai and Biogen are widely collaborating on the joint development and commercialization of AD treatments. Eisai serves as the lead in the co-development of BAN2401, an anti-Abeta protofibril antibody, while Biogen serves as the lead for co-development of aducanumab, Biogen's investigational anti-Abeta antibody for patients with AD, and the companies plan to pursue marketing authorizations for the two compounds worldwide. If approved, the companies will also co-promote the products in major markets, such as the United States, the European Union and Japan.

About Lemborexant

Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Faster on/off receptor kinetics of lemborexant to orexin receptor 2, which also suppresses non-REM sleep, indicate its potential to be facilitate the onset and maintenance of sleep. As a result of clinical studies, the effect of lemborexant are suggested not only for primary insomnia but also for insomnia which the diseases, such as depression, associated with. Eisai has submitted new drug applications seeking approval of lemborexant for use in the treatment of insomnia disorder in the United States (December 2018), Japan (March 2019), and Canada (August 2019), respectively. Additionally, a Phase II clinical study of lemborexant in patients with ISWRD associated with mild to moderate Alzheimer's dementia is underway.

About collaboration between Eisai and Sysmex

Eisai and Sysmex have entered into a comprehensive non-exclusive collaboration agreement aimed at the creation of new diagnostics in the field of dementia in February, 2016. Leveraging each other's technologies and knowledge, the two companies aim to discover next-generation diagnostics that will enable early diagnosis, selection of treatment options and the regular monitoring of the effects of treatment for dementia.

HISCLTM is a trademark of Sysmex Corporation.

About Eisai

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.

For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.

Contact:Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120

Copyright 2019 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

VinAI Announces Scientific Research at the World’s No.1 Conference on Artificial Intelligence - NeurIPS 2019

HANOI, VIETNAM - Media OutReach - 13 December 2019 - VinAI Research (directly under Vingroup) has just announced the first two scientific research results at NeurIPS - the world's No. 1 ...

Why is Toyota Developing Humanoid Robots?

Toyota City, Japan, Dec 13, 2019 - (JCN Newswire) - Have you ever heard of T-HR3?First launched by Toyota in 2017, it's a humanoid robot capable of flexible movements that mirror the action...

Not Taking a Break: Archipelago Signs Three New Deals Just Bef...

JAKARTA, Indonesia, Dec. 13, 2019/PRNewswire-AsiaNet/-- While elsewhere the 2019 yearbooks are written and done as everyone heads into the year-end holidays, Business Developers of Archipela...

Ucommune Wins Prestigious Harvard Business Review Ram Charan M...

SANYA, China, Dec. 13, 2019 /PRNewswire-AsiaNet/ -- Dr. Daqing Mao, the founder and chairman of Ucommune, was bestowed with the highest honor in Chinese management practice after receiving a...

Blockpass Onboards ADAX for KYC Verification, Lists PASS on Exchange

HONG KONG, Dec 13, 2019 - (ACN Newswire) - Blockpass and ADAX Tech Limited have announced a new working relationship as ADAX integrates the Blockpass KYC Connect solution to provide KYC ser...

FiO Fixes Wine, Gaming and Fitness Industry Pain Points

TAIPEI, Dec. 13, 2019/PRNewswire-AsiaNet/-- Innovative SaaS platform FiO is expected to release details on how its blockchain-onboarding service solves long-existing problems in wine provena...

Future Supply Chain and Nippon Express Strategic Partnership A...

MUMBAI, India and TOKYO, Dec. 13, 2019 /Kyodo JBN-AsiaNet/ -- - Sign Business Collaboration Agreement to Generate Synergies; Nippon Express Has Received All Requisite Approvals to Acquire 22...

TOYOTA GAZOO Racing Rally Challenge Program

TOKYO, Dec 13, 2019 - (JCN Newswire) - The TOYOTA GAZOO Racing Rally Challenge Program takes another significant step in 2020, with Japanese driver Takamoto Katsuta set to drive a Toyota Ya...

OMRON and Square Enix Launch Joint Research on "AI That Helps ...

KYOTO, Japan, Dec. 13, 2019 /Kyodo JBN-AsiaNet/ -- - Table Tennis Robot "Forpheus" Equipped with Joint Research Technology to Be Exhibited at "CES (Consumer Electronics Show) 2020" -OMRON Co...

TransCanna to Maximize Value Proposition with Expansion of Sales, Fulfillment and Distribution Strategy

Vancouver, BC, Dec 13, 2019 - (ACN Newswire) - TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) ("TransCanna" or the "Company") is pleased to announce that it has developed a comprehensive s...

BEATNIQ SUKHUMVIT 32 by SC Asset Ready to Offer Modern Vibe of...

BANGKOK, Dec. 6, 2019 /PRNewswire-AsiaNet/ -- BEATNIQ SUKHUMVIT 32 is a brand new luxury free-hold condominium launched by SC Asset Corporation PLC, Thailand's leading property developer tha...

Mitsubishi Corporation Participates in FPSO Project in Brazil

TOKYO, Dec 13, 2019 - (JCN Newswire) - Mitsubishi Corporation (MC), together with Nippon Yusen Kabushiki Kaisha (NYK Line), has entered into a joint venture with SBM Offshore N.V. (SBM), a ...

Sai Life Sciences Announces Sai Nxt, an Initiative to Transfor...

HYDERABAD, India, Dec. 12, 2019 /PRNewswire-AsiaNet/ -- Sai Life Sciences, one of India's fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced Sai ...

TSG Appoints New CEO to Lead Company's Asia Expansion

AUCKLAND, New Zealand, Dec. 13, 2019 /PRNewswire-AsiaNet/ -- -- TSG anticipates major growth in the Japanese Health & Fitness market-- Tokyo Office is now openTSG, a leading provider of ...

Quark Expeditions, The Only Team To Lead A Solar Eclipse Exped...

TORONTO, Dec. 13, 2019 /PRNewswire-AsiaNet/ -- -- The polar expedition operator will reunite experts from its voyage 16 years ago, for two exclusive total solar eclipse voyages in 2021On Nov...

The World’s Toughest Rowing Race – The Talisker Whisky Atlanti...

SAN SEBASTIAN DE LA GOMERA, Spain, Dec. 13, 2019 /PRNewswire-AsiaNet / -- To support the sponsorship and mark the moment, Talisker hosted a series of events ahead of the race including a Par...

Huami Amazfit Confirms Global Product Launch at CES 2020, Expa...

SHENZHEN, China, Dec. 12, 2019 /PRNewswire-AsiaNet/ -- Huami (NYSE: HMI), one of the world's largest wearables company[1], is gearing up to unveil multiple series of new and innovative produ...

NEC Provides Waiting Time Forecast System at Haneda Airport (Tokyo International Airport)

TOKYO, Dec 12, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) has announced the provision of a "Waiting Time Forecast System" that analyzes and visualizes the status of congestion in a...

Infosys Awarded the 'Excellent Partner Award' by Mazda

TOKYO and BENGALURU, India, December 12 /PRNewswire-AsiaNet/ -- - Recognized for successfully transforming Mazda's global supply chain managementTOKYO and BENGALURU, India, Dec. 12, 2019 /P...